AiCure

R&D Trends

Treeway, LACDR collaborate on ALS therapy development

Thursday, October 16, 2014 02:36 PM

Treeway, a Netherlands-based, amyotrophic lateral sclerosis (ALS) R&D strategy-focused company, and the Leiden Academic Center for Drug Research (LACDR) at the University of Leiden, the Netherlands, have formed a collaboration focused on the optimization of clinical trial designs and data analysis for ALS through the use of population disease progression models. Both parties aim to obtain a better understanding of the disease by developing ALS physiology-based disease models and test the effect of interventions in the different identified pathways.

More... »


Servier Canada opens Clinical Development Center in Montreal

Thursday, October 16, 2014 02:34 PM

Servier Canada, the Canadian subsidiary of Servier, has opened its new Clinical Development Center in Montreal.

More... »

CenterWatch

Report: metastatic breast cancer research underfunded

Thursday, October 16, 2014 02:32 PM

While metastatic breast cancer (MBC) claims the lives of 40,000 women and men in America every year and 20-30% of those diagnosed with early stage breast cancer will go on to develop recurrent, metastatic disease, awareness remains low and only 7.1% of breast cancer research investments over the last dozen years were focused on MBC, according to MBC Alliance’s report Changing the Landscape for People Living with Metastatic Breast Cancer.

More... »

Moderna, Karolinska Institute to collaborate on messenger RNA therapeutics

Thursday, October 16, 2014 02:30 PM

Moderna Therapeutics, a Cambridge, Mass.-based pharma, has formed a strategic, long-term collaboration with Karolinska Institute (KI) and Karolinska University Hospital (KUH), both in Sweden, for the discovery and development of innovative drugs using Moderna's messenger RNA (mRNA) Therapeutics technology. mRNA Therapeutics enable the in vivo production of both intracellular proteins and secreted proteins.

More... »

NIH awards $15.6 million for pulmonary research program

Thursday, October 16, 2014 02:29 PM

The NIH has awarded up to $15.6 million in grants over five years to the University of North Carolina, Chapel Hill (UNC-CH) and the University of Colorado, Denver (UCD) to conduct research with mucolytic agents discovered by Parion Sciences, a Durham, N.C.-based company focused on pulmonary and ocular diseases, and to enable Investigational New Drug applications for Parion's molecules.

More... »

New U.K. health campaign urges people with diabetes to 'TALK Hypos'

Thursday, October 16, 2014 02:27 PM

The TALK Hypos awareness campaign has launched in the U.K., supported by Novo Nordisk and Diabetes U.K., encouraging people with diabetes to report hypoglycemia (hypos) to their doctor or nurse.

More... »

WILEX subsidiary Heidelberg Pharma, Roche extend collaboration

Thursday, October 16, 2014 09:00 AM

Wilex’s Germany-based subsidiary Heidelberg Pharma and Roche have extended an existing 2013 license agreement to apply the antibody drug conjugate (ADC) technology for the further development of Roche antibodies. The aim is to identify and develop novel Antibody Targeted Amanitin Conjugates (ATACs) based on Heidelberg Pharma's patented technology to couple α-Amanitin to antibodies.

More... »

CytRx launches discovery laboratory to develop anti-cancer drug platform

Thursday, October 16, 2014 08:31 AM

CytRx, a Los Angeles-Calif.-based biopharmaceutical R&D company specializing in oncology, has commenced operations at its new discovery laboratory in Freiburg, Germany. The new laboratory will conduct discovery and translational research to create drug candidates that utilize novel linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors.

More... »

Astellas, Harvard Medical School investigator collaborate

Thursday, October 16, 2014 07:30 AM

Astellas Pharma, based in Tokyo, Japan, has formed a research collaboration with an investigator at Harvard Medical School in Boston, Mass., focused on discovering the pathologic mechanism for retinitis pigmentosa and identification of new therapeutic targets. Astellas and Harvard aim to provide a new treatment option, possibly gene therapy, to retinitis pigmentosa patients who have difficulty maintaining good vision.  

More... »

CCRM, RepliCel to partner on development of cell therapies for tendon repair

Thursday, October 16, 2014 06:30 AM

RepliCel Life Sciences, a Vancouver-based clinical stage regenerative medicine company focused on the development of autologous cell therapies, is the newest member of the Center for Commercialization of Regenerative Medicine’s (CCRM) industry consortium, a Canadian not-for-profit organization.

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs